AstraZeneca PLC (AZN)vsMettler-Toledo International Inc (MTD)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
MTD
Mettler-Toledo International Inc
$1,293.52
+1.01%
HEALTHCARE · Cap: $26.56B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 1384% more annual revenue ($61.37B vs $4.13B). MTD leads profitability with a 21.9% profit margin vs 17.0%. AZN appears more attractively valued with a PEG of 1.28. MTD earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy60
out of 100
Grade: C+
MTD
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Intrinsic value data unavailable for MTD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Strong operational efficiency at 31.2%
Safe zone — low bankruptcy risk
Every $100 of equity generates 30 in profit
Keeps 22 of every $100 in revenue as profit
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Expensive relative to growth rate
Moderate valuation
4.5% revenue growth
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : MTD
The strongest argument for MTD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 21.9% and operating margin at 31.2%.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : MTD
The primary concerns for MTD are PEG Ratio, P/E Ratio, Revenue Growth. Debt-to-equity of 164.70 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while MTD is a value play — different risk/reward profiles.
MTD carries more volatility with a beta of 1.22 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
MTD scores higher overall (64/100 vs 60/100), backed by strong 21.9% margins. AZN offers better value entry with a 18.4% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Mettler-Toledo International Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Mettler Toledo (NYSE: MTD) is a multinational manufacturer of scales and analytical instruments. It is the largest provider of weighing instruments for use in laboratory, industrial, and food retailing applications. The company also provides various analytical instruments, process analytics instruments, and end-of-line inspection systems.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?